a2b694
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2024 (NCT06051695)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Mesothelioma, Malignant · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
Mechanism of action
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06051695 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2024 | A2 Biotherapeutics Inc., TEMPUS |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| A2 Biotherapeutics Inc. | For profit | 1 | 1 | 1 | 2024 |
| TEMPUS | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1